Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ZYUS Life Sciences ( (TSE:ZYUS) ) just unveiled an announcement.
ZYUS Life Sciences has appointed Dr. Julie Stakiw as Chief Medical Officer to lead the strategic and medical oversight of its clinical development program, particularly the Phase 2 UTOPIA trial for its lead drug product candidate, Trichomylin® softgel capsules. Dr. Stakiw’s extensive experience in oncology and her patient-centered approach are expected to significantly contribute to the advancement of non-opioid cancer pain therapies, aligning with ZYUS’ commitment to improving patient outcomes.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a clinical-stage life sciences company focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company aims to secure intellectual property protection and regulatory approval for non-opioid-based pharmaceutical solutions, enhancing shareholder value and transforming patients’ lives.
Average Trading Volume: 18,200
Technical Sentiment Signal: Sell
Current Market Cap: C$47.74M
For detailed information about ZYUS stock, go to TipRanks’ Stock Analysis page.